GALWAY, Ireland, Nov. 5, 2024 /PRNewswire/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced that it will report financial results for its second quarter of fiscal year 2025 on Tuesday, November 19, 2024. A news release will be issued at approximately 5:45 a.m. Central Standard Time (CST) and will be available at https://news.medtronic.com. The news release will include summary financial information for the company's second quarter of fiscal year 2025, which ended on Friday, October 25, 2024.

GALWAY, Ireland, Nov. 5, 2024 /CNW/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced that it will report financial results for its second quarter of fiscal year 2025 on Tuesday, November 19, 2024. A news release will be issued at approximately 5:45 a.m. Central Standard Time (CST) and will be available at https://news.medtronic.com. The news release will include summary financial information for the company's second quarter of fiscal year 2025, which ended on Friday, October 25, 2024.

The Symplicity ™ blood pressure procedure offers patients a new adjunct approach to lowering blood pressure 

GALWAY, Ireland, Nov. 1, 2024 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced that the Centers for Medicare & Medicaid Services (CMS) has granted transitional pass-through (TPT) payment for the Medtronic Symplicity Spyral™ renal denervation (RDN) catheter, used in the Symplicity™ blood pressure procedure, under the Medicare Hospital Outpatient Prospective Payment System. TPT payment, which will be effective for up to three years beginning January 1, 2025, aims to support patient access to new and innovative technology, including devices granted Breakthrough Device Designations like the Symplicity Spyral RDN system.

Company commits to advancing clinical data for Symplicity™ with the SPYRAL Gemini clinical trial and expansion of the GSR-DEFINE clinical trial

GALWAY, Ireland and WASHINGTON, Oct. 28, 2024 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced new, long-term data from its SPYRAL HTN-ON MED clinical trial that showed subjects who underwent radiofrequency renal denervation with the Symplicity™ Spyral renal denervation (RDN) system had significantly greater reductions in 24-hr ambulatory systolic blood pressure (ABPM), and office-based systolic blood pressure (OSBP) compared to sham patients at two years. The data were presented as a part of the 2024 Transcatheter Cardiovascular Therapeutics Conference (TCT).

GALWAY, Ireland, Oct. 24, 2024 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced United States Food and Drug Administration (FDA) approval of the Affera™ Mapping and Ablation System with Sphere-9™ Catheter, an all-in-one, high-density (HD) mapping and pulsed field (PF) and radiofrequency (RF) ablation catheter for treatment of persistent atrial fibrillation (AFib) and for RF ablation of cavotricuspid isthmus (CTI) dependent atrial flutter.

Customers are being notified of the importance of checking built-in alerts and alarms for battery status and to contact Medtronic for pump replacement if affected by this issue

GALWAY, Ireland, Oct. 4, 2024 /CNW/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, voluntarily issued a field action starting on July 31, 2024, notifying global customers of its MiniMed™ 600 series or 700 series insulin pumps to follow their pump's built-in alerts and alarms for battery status and to contact Medtronic if they observe changes in the battery life of their pump. Medtronic began investigating this issue upon receiving customer reports of shortened battery life and a comprehensive analysis found that pumps that have been dropped, bumped, or experienced physical impact even once may result in shortened battery life due to damage to internal electrical components. This electrical issue also causes battery alerts to occur when less battery life remains than the User Guide states. This may result in the pump stopping insulin delivery significantly sooner than usually expected and could lead to health risks like hyperglycemia or diabetic ketoacidosis (DKA), potentially requiring medical intervention. Most recently, Medtronic has received 170 reports of hyperglycemia >400mg/dL and 11 reports of diabetic ketoacidosis from January 2023 to September 2024 in the US potentially related to this issue. The FDA has classified this action as a class I recall.

Customers are being notified of the importance of checking built-in alerts and alarms for battery status and to contact Medtronic for pump replacement if affected by this issue

GALWAY, Ireland, Oct. 4, 2024 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, voluntarily issued a field action starting on July 31, 2024, notifying global customers of its MiniMed™ 600 series or 700 series insulin pumps to follow their pump's built-in alerts and alarms for battery status and to contact Medtronic if they observe changes in the battery life of their pump. Medtronic began investigating this issue upon receiving customer reports of shortened battery life and a comprehensive analysis found that pumps that have been dropped, bumped, or experienced physical impact even once may result in shortened battery life due to damage to internal electrical components. This electrical issue also causes battery alerts to occur when less battery life remains than the User Guide states. This may result in the pump stopping insulin delivery significantly sooner than usually expected and could lead to health risks like hyperglycemia or diabetic ketoacidosis (DKA), potentially requiring medical intervention. Most recently, Medtronic has received 170 reports of hyperglycemia >400mg/dL and 11 reports of diabetic ketoacidosis from January 2023 to September 2024 in the US potentially related to this issue. The FDA has classified this action as a class I recall.

GALWAY, Ireland and SYDNEY, Sept. 27, 2024 /CNW/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced the presentation of clinical study results demonstrating a high rate of durable lesion formation for the PulseSelect™ Pulsed Field Ablation (PFA) System in treating atrial fibrillation (Afib). Invasive remapping conducted approximately two months post-ablation with the PulseSelect PFA System demonstrated durable isolation in 98% of pulmonary veins (PV) and 96% of patients had all veins isolated.

GALWAY, Ireland and SYDNEY, Sept. 27, 2024 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced the presentation of clinical study results demonstrating a high rate of durable lesion formation for the PulseSelect™ Pulsed Field Ablation (PFA) System in treating atrial fibrillation (Afib). Invasive remapping conducted approximately two months post-ablation with the PulseSelect PFA System demonstrated durable isolation in 98% of pulmonary veins (PV) and 96% of patients had all veins isolated.

GALWAY, Ireland and CHICAGO, Sept. 25, 2024 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, announced today at the North American Spine Society (NASS) 39th Annual Meeting in Chicago the commercial launch of several software, hardware, and imaging innovations. These enhancements are designed to advance AiBLE™, the Medtronic smart ecosystem of innovative navigation, robotics, data and AI, imaging, software and implants that enable more predictable outcomes in spine and cranial procedures. In line with its commitment to increasing the quality of care for patients with spinal conditions, Medtronic also announced a partnership with Siemens Healthineers to explore opportunities to further expand access to advanced pre- and post-operative imaging technologies for spine care.

GALWAY, Ireland and CHICAGO, Sept. 25, 2024 /CNW/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, announced today at the North American Spine Society (NASS) 39th Annual Meeting in Chicago the commercial launch of several software, hardware, and imaging innovations. These enhancements are designed to advance AiBLE™, the Medtronic smart ecosystem of innovative navigation, robotics, data and AI, imaging, software and implants that enable more predictable outcomes in spine and cranial procedures. In line with its commitment to increasing the quality of care for patients with spinal conditions, Medtronic also announced a partnership with Siemens Healthineers to explore opportunities to further expand access to advanced pre- and post-operative imaging technologies for spine care.

GALWAY, Ireland, Aug. 27, 2024 /CNW/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced it will participate in the 2024 Wells Fargo Healthcare Conference on Wednesday, September 4, 2024.

Geoff Martha, Medtronic chairman and chief executive officer, will answer questions on the medtech industry and on the company beginning at approximately 11:55 a.m. EDT (12:55 p.m. CDT).

A live webcast of the Q&A session will be available on September 4, 2024, by clicking on the Events link at http://investorrelations.medtronic.com. An archive of the session will be available on the same webpage later in the day.

GALWAY, Ireland, Aug. 27, 2024 /PRNewswire/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced it will participate in the 2024 Wells Fargo Healthcare Conference on Wednesday, September 4, 2024.

Geoff Martha, Medtronic chairman and chief executive officer, will answer questions on the medtech industry and on the company beginning at approximately 11:55 a.m. EDT (12:55 p.m. CDT).

A live webcast of the Q&A session will be available on September 4, 2024, by clicking on the Events link at http://investorrelations.medtronic.com. An archive of the session will be available on the same webpage later in the day.

Product innovation driving growth across diversified health tech portfolio, including Automated Insulin Delivery, Transcatheter Aortic Valve Replacement, Pulsed Field Cardiac Ablation, Pain Stimulation, and Deep Brain Stimulation

GALWAY, Ireland, Aug. 20, 2024 /CNW/ -- Medtronic plc (NYSE: MDT) today announced financial results for its first quarter (Q1) of fiscal year 2025 (FY25), which ended July 26, 2024.

Key Highlights

Product innovation driving growth across diversified health tech portfolio, including Automated Insulin Delivery, Transcatheter Aortic Valve Replacement, Pulsed Field Cardiac Ablation, Pain Stimulation, and Deep Brain Stimulation

GALWAY, Ireland, Aug. 20, 2024 /PRNewswire/ -- Medtronic plc (NYSE: MDT) today announced financial results for its first quarter (Q1) of fiscal year 2025 (FY25), which ended July 26, 2024.

Key Highlights

GALWAY, Ireland, Aug. 16, 2024 /CNW/ -- The board of directors of Medtronic plc (NYSE:MDT) on Thursday, August 15, 2024, approved the company's cash dividend for the second quarter of fiscal year 2025 of $0.70 per ordinary share. This quarterly declaration is consistent with the dividend increase announcement made by the company in May 2024. Medtronic is a constituent of the S&P 500 Dividend Aristocrats index, having increased its annual dividend payment for the past 47 consecutive years. The dividend is payable on October 11, 2024, to shareholders of record at the close of business on September 27, 2024.

GALWAY, Ireland, Aug. 16, 2024 /PRNewswire/ -- The board of directors of Medtronic plc (NYSE:MDT) on Thursday, August 15, 2024, approved the company's cash dividend for the second quarter of fiscal year 2025 of $0.70 per ordinary share. This quarterly declaration is consistent with the dividend increase announcement made by the company in May 2024. Medtronic is a constituent of the S&P 500 Dividend Aristocrats index, having increased its annual dividend payment for the past 47 consecutive years. The dividend is payable on October 11, 2024, to shareholders of record at the close of business on September 27, 2024.

GALWAY, Ireland, Aug. 12, 2024 /CNW/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced that it will report financial results for its first quarter of fiscal year 2025 on Tuesday, August 20, 2024. A news release will be issued at approximately 5:45 a.m. Central Daylight Time (CDT) and will be available at https://news.medtronic.com. The news release will include summary financial information for the company's first quarter of fiscal year 2025, which ended on Friday, July 26, 2024.

GALWAY, Ireland, Aug. 12, 2024 /PRNewswire/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced that it will report financial results for its first quarter of fiscal year 2025 on Tuesday, August 20, 2024. A news release will be issued at approximately 5:45 a.m. Central Daylight Time (CDT) and will be available at https://news.medtronic.com. The news release will include summary financial information for the company's first quarter of fiscal year 2025, which ended on Friday, July 26, 2024.